However, a subgroup analysis revealed that treatment response (defined as ≥50% reduction in the 17-item Hamilton Depression Rating Scale at any point during treatment) correlated with baseline elevated C-reactive protein (CRP) [62% (8/13) in the infliximab (IFX) group versus 33% (3/9) in placebo-treated patients (p = 0.19)]. This evidence concerns the gene CRP and depressive symptom measurement.